Development of liver cancer treatment using Vasohibin-2 targeting antisense oligonucleotide

2015 Fiscal Year Final Research Report

• Project/Area Number: 26860205
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Pathological medical chemistry
• Research Institution: Tohoku University
• Principal Investigator: Horie Sachiko 東北大学, 加齢医学研究所, 産学官連携研究員 (90451640)
• Research Collaborator: SATO YASUFUMI 東北大学, 加齢医学研究所, 教授 (50178779) ; OBIKA SATORU 大阪大学, 薬学研究所, 教授 (80243252)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: Vasohibin / BNA修飾アンチセンスオリゴヌクレオチド / 抗腫瘍効果 / 肝臓がん

Outline of Final Research Achievements

Vasobihin-2 (VASH2), a pro-angiogenic factor, is expressed in cancer cells and promotes tumor growth. This study has shown that the systemic administration of bridged nucleic acids (BNA)-based antisense oligonuculeotide targeting VASH2 accumulated in the liver and exhibited anti-tumor effects on the orthotopic inoculation of a human hepatocellular carcinoma cell line and a metastatic liver cancer model with a splenic inoculation of a human colon carcinoma cell line. Our findings will provide new information and strategy that can be exploited for the development of primary and metastatic liver cancer treatment targeting VASH2.

Free Research Field

DDS